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Abstract 
Background: Chemokines and chemokine receptors play important roles in autoimmune diseases; however, their 
role in immune thrombocytopenia (ITP) is unclear. High-dose dexamethasone (HD-DXM) may become a first-line 
therapy for adult patients with ITP, but the effect of HD-DXM on chemokines in ITP patients is unknown. Our aim 
was to investigate the mechanism of pulsed HD-DXM for management of ITP, specifically regarding the chemokine 
pathways.
Methods: Th1-/Th2-associated chemokine and chemokine receptor profiles in ITP patients before and after pulsed 
HD-DXM was studied. Plasma levels of CCL5 and CXCL11 (Th1-associated) and of CCL11 (Th2-associated) were deter-
mined by ELISA. Gene expression of these three chemokines and their corresponding receptors CCR5, CXCR3, and 
CCR3, in peripheral blood mononuclear cells (PBMCs) was determined by quantitative RT-PCR.
Results: Thirty-three of the thirty-eight ITP patients responded effectively to HD-DXM (oral, 40 mg/day, 4 days). In ITP 
patients, plasma CXCL11 levels increased, while CCL11 and CCL5 decreased compared to controls (P < 0.05). Simi-
larly, gene expression of CXCL11 and its receptor CXCR3 increased, while CCL11 and CCR3 decreased (P < 0.05). CCL5 
expression did not significantly change; however, expression of its receptor CCR5 increased (P < 0.05). Interestingly, 
in the patients who responded to pulsed HD-DXM, CXCL11 and CXCR3 expression was down-regulated, while CCL11 
and CCR3 expression was up-regulated (P < 0.05). Meanwhile, CCL5 expression was up-regulated and CCR5 was 
down-regulated by HD-DXM (P < 0.05).
Conclusions: The abnormal profiles of Th1-/Th2-associated chemokines and chemokine receptors may play impor-
tant roles in the pathogenesis of ITP. Importantly, regulating Th1 polarization by pulsed HD-DXM may represent a 
novel approach for immunoregulation in ITP.
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Background
Immune thrombocytopenia (ITP) is an acquired autoim-
mune-mediated bleeding disorder, mainly characterized 
by anti-platelet antibody-mediated thrombocytopenia 
in the reticuloendothelial system [1]. Interestingly, it has 
been shown that the destruction of platelets is associ-
ated with enhanced T-helper 1 (Th1) expression and an 
elevated Th1/Th2 ratio in ITP patients [2, 3]. However, 
expression of chemokines and chemokine receptors asso-
ciated with the Th1/Th2 imbalance, particularly relating 
to immune regulation by modified application of gluco-
corticoids, has yet to be explored.
Chemokines and their receptors are involved in cel-
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regulation of apoptosis, T cell differentiation, leuko-
cyte trafficking, and cytokine production [4]. For exam-
ple, chemokine CCL5 is not only required for attracting 
CCR5+ T cells but is also essential for their activation 
[5]. CCR5 is specifically expressed on Th1 cells and has 
been reported as a critical chemokine receptor in sev-
eral autoimmune diseases with polarization of Th1 cells 
such as rheumatoid arthritis, multiple sclerosis, Crohn’s 
disease and oral lichen planus [6–8]. CXCL10 expression 
is essential for Th1 cell differentiation [9, 10]. CXCL11 is 
overexpressed in Th1-dominated skin disorders, such as, 
psoriasis, lichen planus, and atopic dermatitis [11–13]. 
Moreover, CXCL11 is the most potent chemoattractant 
and has the highest receptor binding affinity for CXCR3 
[14]. CXCR3, a marker for activated T lymphocytes, is 
characteristically expressed on Th1 and CD8+ T cells [15, 
16] and is required for generation of interferon-γ (IFN-
γ) -secreting Th1 cells in  vivo [9]. In contrast, CCR3 is 
predominantly expressed on Th2 cells [17]. Recently, 
by characterizing Th1-associated chemokine recep-
tors CXCR3 and CCR5, and Th2-associated chemokine 
receptor CCR3, we demonstrated that the abnormal 
expression of Th1/Th2 chemokine receptors may partici-
pate in the splenic immune dysregulation in ITP patients 
[18].
Glucocorticoid therapy is still the primary choice for 
treatment of ITP. Due to the poor long-term sustainabil-
ity and possible adverse effects of long-term administra-
tion of corticosteroids [19], recent reports suggested that 
high-dose dexamethasone (HD-DXM) might be a prom-
ising regimen to replace the classical prednisone therapy 
[20–22]. Here, we investigated Th1- and Th2-associated 
chemokines and their receptors in peripheral blood of 
ITP patients. Specifically, we investigated whether HD-
DXM could rectify the abnormal Th1-/Th2-associated 
chemokine and chemokine receptor profile in ITP.
Methods
Patients and controls
Between December 2014 and August 2016, 38 patients 
(12 males and 26 females, age range 12–71 years, median 
age 40.5 years) with active ITP in Shenzhen Baoan Hospi-
tal Affiliated to the Southern Medical University and the 
Second Hospital of Shandong University were enrolled. 
Patients’ platelet counts ranged from 2 to 34  ×  109/L, 
with a median count of 10 × 109/L. All patients required 
treatment because of clinically significant bleeding. All 
of the cases met the diagnosis criteria of ITP as previ-
ously described [23]. None of them had received any 
corticosteroid or immunosuppressive therapy within 
the 3  months prior to sampling. Patients with diabetes, 
hypertension, cardiovascular diseases, pregnancy, active 
infection, or connective tissue diseases, such as systemic 
lupus erythematosus, were excluded. The clinical features 
of the patients are shown in Table 1.
The control group consisted of 31 healthy adult volun-
teers (11 males and 20 females, age range 21–53  years, 
median 31.5  years), whose platelet counts ranged 
from 148 to 342  ×  109/L, with the median count of 
196 × 109/L.
Treatment regimen
Dexamethasone (DXM, 40  mg/day) was administered 
orally for four consecutive days. No maintenance or 
other treatment modality was used. Initial response was 
evaluated 2  weeks after treatment initiation. An effec-
tive response was defined as a platelet count greater than 
30 × 109/L, at least a twofold increase compared to base-
line, and an absence of bleeding [24].
Reagents and antibodies
Lymphoprep was obtained from Hao Yang Biological 
Manufacturer, Tianjin, China. Human CCL5, CXCL11, 
and CCL11 ELISA kits were purchased from R&D Sys-
tems, USA. TriZol reagent for total RNA was provided 
by Invitrogen, CA, USA. PrimeScript™ RT reagent Kit, 
SYBR Premix Ex Taq TM II were supplied by TaKaRa, 
Japan. Oligonucleotide primers for real-time PCR for 
CCL5, CXCL11, CCL11, CCR5, CXCR3, CCR3, and 
β-actin were synthesized by TaKaRa, Japan. Phosphate-
buffered saline, fetal bovine serum, trypsin–EDTA and 
RPMI 1640 was provided by Gibco, USA. The microplate 
reader was supplied by Thermo Scientific, USA.
PBMCs and plasma preparation
Peripheral blood mononuclear cells (PBMCs) were puri-
fied from heparinized venous blood samples immediately 
following collection using Lymphoprep density gradient 
centrifugation. Plasma was isolated from fresh samples 
by centrifugation and stored at −80 °C until use.
Chemokine secretion
Plasma concentrations of CCL5, CXCL11, and CCL11 in 
active patients, patients who responded to HD-DXM, and 
controls were evaluated using a matched ELISA kit. All 
procedures were performed according to the manufac-
turer’s instructions. Each sample was tested in duplicate 
and optical densities were read using a microplate reader.
Assay of chemokine mRNA expression
Total RNA was extracted from PBMCs with TriZol 
according to the manufacturer’s instructions. cDNA was 
reversely transcribed from total RNA using an eppen-
dorf Realplex2 PCR Detection System and the Prime-
Script™ RT reagent kit. Following the manufacturer’s 
protocol, real-time PCR was performed to determine 
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the expression of chemokine mRNA with SYBR Premix 
Ex Taq™ II. Reverse transcription was carried at 42  °C 
for 5  min. PCR was performed as follows: initial dena-
turation 30  s at 95  °C, and for 40 cycles of 5  s at 95  °C 
for denaturation and 30  s at 60  °C for transcription. All 
samples were measured in triplicate. The amount of 
chemokine mRNA was normalized with β-actin and 
expressed as relative quantification (RQ): RQ  =  2−ΔΔct. 
The primer sequences for CCR5, CXCR3, CCR3, CCL5, 
CXCL11, CCL11, and β-actin are listed in Table 2.
Table 1 Clinical characteristics of patients with ITP
EC ecchymoses; GC glucocorticoid; PT petechiae; EP epistaxis; GUH genitourinary hemorrhage; GIH gastrointestinal hemorrhage; GH gingival hemorrhage
Patient Gender Age Platelets (×109/L) Bleeding symptoms Major therapy Platelets (×109/L)
Before treatment After treatment
1 F 54 23 EC GC 118
2 F 37 6 EC, PT GC 154
3 F 23 15 EC, EP GC 98
4 F 58 18 EP, GUH GC 222
5 F 48 3 EC, GUH GC 245
6 M 67 12 PT GC 97
7 F 40 10 PT GC 56
8 M 59 4 EC GC 234
9 F 60 27 EC, GUH GC 67
10 M 70 10 EC, PT GC 21
11 M 49 9 PT GC 180
12 M 12 34 EC GC 78
13 F 13 21 EC GC 203
14 F 26 10 EC, GIH GC 82
15 F 28 19 EC GC 168
16 M 65 20 EC, GIH GC 166
17 M 42 11 PT GC 267
18 F 17 9 EC GC 80
19 F 56 2 PT GC 9
20 M 61 27 PT GC 174
21 F 63 10 EC, GH GC 199
22 F 50 14 EC, PT GC 143
23 M 31 11 EC GC 20
24 F 26 25 PT GC 156
25 F 71 21 PT GC 151
26 F 51 28 EC, GUH GC 32
27 F 28 8 PE, PT, ET GC 103
28 F 24 9 EC, EP GC 197
29 F 29 16 PT GC 173
30 F 34 22 PT GC 129
31 F 41 7 PE, PT GC 301
32 F 20 5 EC, GUH GC 24
33 M 25 23 PT GC 71
34 M 37 3 PT GC 96
35 F 19 2 EC, PT GC 136
36 M 33 7 PT GC 84
37 F 46 16 PT GC 183
38 F 42 10 PT GC 158
Median 40.5 10 148.5
Range 12–71 2–34 9–301
Page 4 of 8Liu et al. J Transl Med  (2016) 14:301 
Statistical analysis
The Statistical Package for the Social Sciences version 
19.0 (SPSS Inc., Chicago, IL) was used for statistical 
analysis of experimental data. Values are presented as 
mean  ±  SD. The date of plasma chemokine levels and 
mRNA levels among the active ITP groups and normal 
controls were normally distributed. The comparison 
between two groups was conducted by t test, measure-
ment data were compared by ANOVA with Bonferroni 
test analysis among multiple groups. Briefly, ANOVA 
analysis was for comparison among active ITP, nor-
mal controls, and responders, and Bonferroni test was 
for comparison between any of two groups. Values of 
P < 0.05 were considered statistically significant.
Results
Therapeutic effect of HD‑DXM
Out of all 38 patients, 33 cases (10 males and 23 females, 
median age 38.5  years, range 12–71  years) responded 
effectively to the HD-DXM therapy, according to the 
standard definition [19]. In these responders, platelet 
counts ranged from 56 to 301 ×  109/L, with a median 
count of 155 × 109/L, as shown in Table 1. No bleeding 
or other complications were apparent, such as metabo-
lized abnormality of multiple systems. Withdrawal 
symptoms were not observed throughout the treatment 
either.
Plasma levels of CCL5, CXCL11, and CCL11
Compared to normal controls, plasma CCL5 levels 
were reduced in the active ITP group (126.18  ±  19.84 
vs 455.54 ± 68.29 pg/mL). Plasma CCL5 in ITP patients 
who responded well to HD-DXM (responders) improved 
(334.08 ± 53.63 pg/mL) but was still lower than control 
(Fig. 1a).
Compared to control, CXCL11 levels were increased in 
active ITP patients (277.84 ± 37.78 vs 109.83 ± 20.30 pg/
mL). In responders, CXCL11 levels decreased 
(145.53 ± 18.44 pg/mL), but were still higher than con-
trols (Fig. 1b).
Compared to control, CCL11 levels in active ITP 
patients were lower than in controls (155.60 ±  13.22 vs 
Table 2 Primer sequences















































































































Fig. 1 Plasma CCL5, CXCL11, and CCL11 levels. a Compared to 
normal controls, CCL5 levels were reduced in the active ITP. In 
responders (ITP patients who responded well to HD-DXM), CCL5 
improved significantly but still lower than control (P = 0.000 < 0.05). 
b Compared to control, CXCL11 levels were increased in active ITP 
patients (P = 0.000 < 0.05). In responders, CXCL11 levels decreased, 
but were still higher than controls (P = 0.018). c Compared to control, 
CCL11 levels in active ITP patients were lower than in controls 
(P = 0.000 < 0.05). Responders had significantly higher CCL11 levels 
than active ITP patients that were not significantly different from 
control (P = 0.255 > 0.05). Asterisk represents P < 0.01 vs control and 
responders, # P < 0.05 and ## P < 0.01 vs control
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271.47  ±  20.48  pg/mL). Responders had significantly 
higher CCL11 levels (248.88 ± 25.53 pg/mL) than active 
ITP patients that were not significantly different from 
control (Fig. 1c).
CCL5, CXCL11, and CCL11 mRNA expression
Chemokine mRNA levels in PBMCs were determined by 
qRT-PCR. For CCL5 expression, no significant difference 
was found between any group (1.36 ± 0.31 vs 1.57 ± 0.20 
vs 1.61  ±  0.25, in active ITP, control, and responders. 
Fig. 2a).
Compared to normal controls, CXCL11 mRNA lev-
els were increased in active ITP patients (4.23  ±  0.50 
vs 1.04  ±  0.11). CXCL11 expression in responders was 
significantly decreased (2.03 ± 0.15) compared to active 
ITP, but still higher than controls (Fig. 2b).
Compared to control, CCL11 mRNA levels in 
active ITP patients was reduced (0.53  ±  0.08 vs 












































































































Fig. 2 Relative quantification of mRNA levels of CCL5, CXCL11 and 
CCL11. a No significant difference was found between any groups 
(P = 0.382, 0.390, 1.000 > 0.05, respectively). b Compared to normal 
controls, CXCL11 mRNA levels were increased in active ITP patients 
(P = 0.000 < 0.05). CXCL11 expression in responders was signifi-
cantly reduced compared to active ITP, but still higher than controls 
(P = 0.000 < 0.05, respectively). c Compared to control, CCL11 mRNA 
levels in active ITP patients was reduced (P = 0.000 < 0.05), however, 
CCL11 mRNA levels improved in responders and was not significantly 
different from control (P = 1.000 > 0.05). * P < 0.01 vs control and 




















































































































Fig. 3 Relative quantification of mRNA levels of CCR5, CXCR3, 
and CCR3. a Compared to control, CCR5 mRNA levels in active 
ITP patients were elevated (P = 0.000 < 0.05). In responders, 
CCR5 expression returned to normal levels (P = 1.000 > 0.05). b 
Compared to control, CXCR3 mRNA levels in active ITP patients 
were elevated (P = 0.000 < 0.05). CXCR3 expression in responders 
decreased (P = 0.000 < 0.05), but was still higher than that in control 
(P = 0.000 < 0.05). c Compared to control, CCR3 mRNA levels in 
active ITP decreased (P = 0.000 < 0.05); after treatment with HD-
DXM, CXCR3 expression in responders increased (P = 0.000 < 0.05). 
* P < 0.01 vs control and responders, ## P < 0.01 vs control
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responders and was not significantly different from con-
trol (0.98 ± 0.13) (Fig. 2c).
CCR5, CXCR3, and CCR3 mRNA expression
Compared to control, as mRNA expression of the Th1-
associated chemokine receptors, both of CCR5 and 
CXCR3 were elevated in active ITP patients (2.05 ± 0.20 
vs 1.03 ± 0.06, 4.06 ± 0.23 vs 1.06 ± 0.08, respectively) 
(Fig. 3a, b). In responders, CCR5 expression returned to 
normal levels (1.06 ± 0.15, Fig. 3a). CXCR3 expression in 
responders decreased (2.43 ± 0.11), but was still higher 
than that in control (Fig. 3b).
Compared to control, as one of the Th1-associated 
chemokine receptors, CCR3 mRNA levels in active 
ITP decreased (0.63 ±  0.07 vs 1.01 ±  0.04); after treat-
ment with HD-DXM, CXCR3 expression in responders 
increased significantly (1.20 ± 0.12, Fig. 3c).
Discussion
ITP is an immune-mediated acquired disease charac-
terized by a persistent or transient decrease of platelet 
count. In this study, we found an abnormal profile of 
Th1- and Th2-associated chemokines and their receptors 
in peripheral blood of ITP patients. Further, we demon-
strated that HD-DXM can rectify the abnormal Th1-/
Th2-associated chemokine and chemokine receptor pro-
file in ITP.
Our findings showed that 85.71  % of ITP patients 
responded well to pulsed HD-DXM, confirming its 
impressive therapeutic effect. Previously, a high initial 
response was reported in a large study by Cheng et  al. 
[20] after adult ITP patients were treated with a single 
dose of HD-DXM. The international consensus report 
and practice guidelines for ITP have now proposed HD-
DXM therapy as one of the first-line therapeutic options 
for ITP patients [23, 24]. The latest clinical investigation 
showed that in addition to being generally better toler-
ated, HD-DXM resulted in a higher incidence of over-
all initial response and complete response compared to 
prednisone. These findings suggested that HD-DXM may 
be a preferred corticosteroid strategy for first-line man-
agement of adult primary ITP [25].
Although the etiology of ITP is multifactorial, many 
researchers have shown that ITP involves Th1 polariza-
tion, characterized by the oligoclonal accumulation of 
Th1 cells [3, 26]. Chemokines and chemokine receptors 
that are involved in T cell differentiation could influence 
the balance of Th1/Th2 [4]. These results prompted us to 
investigate the expression of chemokines and their recep-
tors in ITP patients.
CXCL11 is one of the three ligands of CXCR3, the oth-
ers being CXCL9 and CXCL10. CXCL11 and CXCL10 
may play a role in the accumulation of Th1 cells in 
pulmonary sarcoidosis, a Th1-associated disease [27]. Of 
the three ligands, CXCL11 has the highest receptor bind-
ing affinity for CXCR3 through chemotactic migration 
and transient mobilization of intercellular calcium [28]. 
Here, we detected the status of CXCL11 and its receptor 
CXCR3 in ITP. We found that plasma CXCL11 levels in 
active ITP patients were higher than in controls, suggest-
ing that CXCL11 may be an important chemoattractant 
for effector T cells involved in ITP. Moreover, CXCL11 
acts as an antagonist for CCR3 but an agonist for CXCR3 
[29]. In patients who responded well to pulsed HD-
DXM (responders), plasma CXCL11 and mRNA levels of 
CXCL11 in PBMCs were decreased. Therefore, CXCL11 
may be a potential therapeutic target for ITP, since the 
analogue is that Tizina et  al. [30] successively modelled 
the structural determinants of these interactions of 
CXCL9/CXCR3, CXCL10/CXCR3 and CXCL11/CXCR3 
complexes and their physico-chemical features in order 
to be used for drug design.
CCL5 is a CC chemokine that activates cells by bind-
ing to Th1-associated CCR1 and CCR5 [31]. CCL5/CCR5 
interaction has been reported in a number of Th1-asso-
ciated diseases, such as rheumatoid arthritis, multiple 
sclerosis [32], human immunodeficiency virus 1 (HIV-1) 
infection [33], Crohn’s disease [7], and oral lichen planus 
[8]. In this study, for mRNA levels of CCL5 in PBMCs, 
no significant difference was found between any group; 
however, plasma levels of CCL5 in active ITP patients 
was lower than in controls, perhaps because platelets are 
the principal source of CCL5 [34]. With the increase of 
platelet counts after pulsed HD-DXM treatment, there 
was an increase of CCL5 concentration in plasma. Thus, 
an important role for CCL5 in the pathogenesis of ITP 
is not evident; there are possibly other chemokines [35] 
binding to CCR5 to destroy platelets.
CCL11 is a specific and potent eosinophil chemoat-
tractant that acts exclusively via CCR3 [36]. CCR3 is 
selectively expressed on Th2 subset, so CCL11 and CCR3 
are effectors of the Th2 response. Adzemovic et  al. [37] 
established a congenic rat strain with the Eae18b locus 
containing a chemokine cluster (CCL2, CCL7, CCL11, 
CCL12, and CCL1) from the experimental autoimmune 
encephalomyelitis (EAE)- resistant PVG rat strain. The 
group observed a milder disease and elevated CCL11 
mRNA and protein levels in inguinal lymph nodes in the 
Eae18b congenic strain. Increased intrathecal produc-
tion of CCL11 in congenic rats was accompanied by a 
tighter blood brain barrier, reflected by more occludin-
positive blood vessels. In addition, the congenic strain 
showed a reduced antigen specific response and a pre-
dominant anti-inflammatory Th2 phenotype. Our results 
suggest that the reduced expression of CCR3 and the 
decline of CCL11 may be one of the causes of the Th1/
Page 7 of 8Liu et al. J Transl Med  (2016) 14:301 
Th2 imbalance in ITP. Correspondingly, the restoration 
of CCR3 and CCL11 after pulsed HD-DXM suggests the 
rebalancing of Th1/Th2. Thus, upregulation of CCL11 
and CCR3 was associated with a Th2-like immune 
response, which could skew the immune response away 
from the autoimmune state.
Conclusions
Our data suggest that polarization of Th1-associated 
chemokines and chemokine receptors may play impor-
tant roles in the pathogenesis of ITP. Further, rectify-
ing the abnormal chemokine profile associated with the 
Th1/Th2 imbalance by treatment with pulsed HD-DXM 
provides us with new insight into the immunoregulatory 
mechanisms for the treatment of ITP.
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